Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of a acetylcholinesterase levels.

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: A method, a computer implemented method, and a device, all for adaptively testing a subjects neurological state. The method comprising the steps of: administering one or more seed questions; obtaining one or more answer(s) to the one or more seed questions; calculating a score value of a latent subject trait from the answers to the one or more seed questions; the method comprising an adaptive test loop, comprising: (a) selecting, based on the score value, one or more further questions from a bank of questions; (b) administering the one or more further questions to the subject; (c) updating the score value based on the answers to the one or more further questions; (d) determining whether a test completion criteria has been met; wherein the method repeats steps (a)-(d) in sequence until the test completion criteria has been met, and provides an output of the test based on the score value which is indicative of the subjects neurological state.

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: A system for reconstructing vehicle itinerary include a processor and a memory storing instructions, implemented by the processor, to cluster historical trip records into a plurality of clusters, each of the plurality of clusters including a set of historical trip records that describe events occurring within a predetermined time range at one location; identify a sequence of clusters that includes a cluster at each location; and estimate an itinerary for a vehicle based on the sequence of clusters and constraint data describing physical constraints, the itinerary for the vehicle describing a sequence of arrival and departure times at a sequence of locations for the vehicle.

Abstract: The invention describes improved treatments for Frontotemporal dementia based on the use of a methylthioninium compound in combination with a compound which directly modifies synaptic neurotransmission in the brain, such as a symptomatic Alzheimer's disease treatment (e.g. acetylcholinesterase and/or memantine).

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: The invention describes improved treatments for Frontotemporal dementia based on the use of a methylthioninium compound in combination with a compound which directly modifies synaptic neurotransmission in the brain, such as a symptomatic Alzheimer's disease treatment (e.g. acetylcholinesterase and/or memantine).

Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimized pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

Abstract: A system for reconstructing vehicle itinerary include a processor and a memory storing instructions, implemented by the processor, to cluster historical trip records into a plurality of clusters, each of the plurality of clusters including a set of historical trip records that describe events occurring within a predetermined time range at one location; identify a sequence of clusters that includes a cluster at each location; and estimate an itinerary for a vehicle based on the sequence of clusters and constraint data describing physical constraints, the itinerary for the vehicle describing a sequence of arrival and departure times at a sequence of locations for the vehicle.

Abstract: A system for reconstructing vehicle itinerary include a processor and a memory storing instructions, implemented by the processor, to cluster historical trip records into a plurality of clusters, each of the plurality of clusters including a set of historical trip records that describe events occurring within a predetermined time range at one location; identify a sequence of clusters that includes a cluster at each location; and estimate an itinerary for a vehicle based on the sequence of clusters and constraint data describing physical constraints, the itinerary for the vehicle describing a sequence of arrival and departure times at a sequence of locations for the vehicle.

Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

Abstract: The present invention relates generally to methods and materials based on diaminophenothiazines for use in the treatment of Mild Cognitive Impairment (MCI).

Abstract: The present invention relates generally to methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

Abstract: A system for reconstructing vehicle itinerary include a processor and a memory storing instructions, implemented by the processor, to cluster historical trip records into a plurality of clusters, each of the plurality of clusters including a set of historical trip records that describe events occurring within a predetermined time range at one location; identify a sequence of clusters that includes a cluster at each location; and estimate an itinerary for a vehicle based on the sequence of clusters and constraint data describing physical constraints, the itinerary for the vehicle describing a sequence of arrival and departure times at a sequence of locations for the vehicle.

Abstract: The present invention relates generally to methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.

Abstract: The invention provides methods and systems for assessing the efficacy of a pharmaceutical which is putatively disease modifying of a cognitive disorder, for use in the treatment or prophylaxis of that cognitive disorder, the method comprising the steps of: (1) stratifying a subject group into at least 2 sub-groups according to a baseline indicator of likely disease progression, (2) treating members of each subject group with the pharmaceutical for a treatment time frame, (3) deriving psychometric and optionally physiological outcome measures for each treated patient group, (4) comparing the outcomes at (3) with a comparator arm of said sub-groups which is optionally a placebo or minimal efficacy comparator arm, (5) using the comparison in (4) to derive an efficacy measure for the pharmaceutical.